





# Sulfadoxine + pyrimethamine

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > For curative treatment

EMLc

ATC codes: [P01BD51](#)

Indication	Malaria due to Plasmodium vivax <span>ICD11 code: <a href="#">1F81</a></span>
INN	Sulfadoxine + pyrimethamine
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	Only in combination with artesunate 50 mg
Formulations	Oral > Solid: 500 mg + 25 mg tablet
EML status history	First added in 1979 ( <a href="#">TRS 641</a> ) Changed in 1987 ( <a href="#">TRS 770</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Sulfadoxine + pyrimethamine</a> 
DrugBank	<a href="#">Sulfadoxine</a>  , <a href="#">Pyrimethamine</a> 

## Summary of evidence and Expert Committee recommendations

Sulfadoxine + pyrimethamine tablets 500 mg + 25 mg was added to the EMLc for the curative treatment of malaria.

